Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 260

Results For "approval"

2604 News Found

Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.


Lupin launches penicillamine tablets USP
News | March 04, 2021

Lupin launches penicillamine tablets USP

Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).


Bayer delivers robust performance despite pandemic
News | February 26, 2021

Bayer delivers robust performance despite pandemic

The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.


IPA goes all out to develop a future roadmap for pharma sector
News | February 26, 2021

IPA goes all out to develop a future roadmap for pharma sector

Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.


Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda
News | February 26, 2021

Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda

The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.


Pharma industry bullish on complex generics and biosimilars
News | February 25, 2021

Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side


Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


2021 will be a game-changer for pharma industry, says experts
News | February 13, 2021

2021 will be a game-changer for pharma industry, says experts

The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse


Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
News | February 11, 2021

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda

The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.